| Long term prognosis of patients with myocardial infarction and normal coronary angiography: impact of inherited coagulation disorders. | |
| | |
MedLine Citation:
|
PMID: 14961169 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The prognosis of patients with myocardial infarction (MI) and normal coronary arteries (NCA) in the presence of an inherited coagulation disorder is unknown. The purpose of this study was to compare the clinical thrombosis outcome of patients with (GpI) or without (GpII), inherited coagulation disorders, who suffered from an acute MI with NCA. Eighty two consecutive patients (mean age 49 +/- 15 years; 29 females) with MI, but NCA, were recruited. Twelve patients (15%) had an inherited coagulation disorder. GpI and GpII were statistically similar regarding age (45 +/- 11 vs 50 +/- 16 years-old), gender (33 vs. 36% female), tobacco consumption (50 vs. 53%), diabetes mellitus (8 vs. 10%), hypertension (25 vs. 17%), obesity (8.3 vs. 14%), family history of coronary heart disease (33 vs. 19%), hypercholesterolemia (50 vs. 21%; p =.08), left ventricular ejection fraction (58 +/- 13 vs. 61 +/- 13%) and spasm (8.3% vs. 17%). All patients were initially treated with antiplatelet agents with the exception of one (8%) in GpI, and 6 (9%) in GpII who were taking oral anticoagulant therapy (ns). The mean follow-up was 57 +/- 26 (range from 2-91 months). During the outcome, 12/78 (15.4%) thrombosis events occurred, including venous thrombosis or pulmonary embolism (1/12 vs. 1/66), reinfarction (2/12 vs. 4/66), and stroke (2/12 vs. 2/66), with two events in one patient (GpI). Kaplan-Meier event-free survival, with combined end-point, defined as venous thrombo-embolic event, reinfarction, or stroke differed between the two groups: 4/12 (33.3%) in GpI and 7/66 (10.6%) in Gp II (p <.02). Patients with MI, NCA and congenital coagulation disorder present a high risk of thrombosis recurrence under antiplatelet agent. |
| | |
Authors:
|
Antoine Da Costa; Brigitte Tardy; Kamel Haouchette; Patrick Mismetti; Alexis Cerisier; Michel Lamaud; Denis Guyotat; Karl Isaaz |
Related Documents
:
|
12100159 - Factor v leiden in central venous catheter-associated thrombosis. 20954129 - Endovascular intervention for central venous cannulation in patients with vascular occl... 20651889 - catheter in the superior vena cava for hemodialysis as a last resort in superior hemith... 1198239 - Tropical thrombophlebitis. the role of relapsing fever in its causation. 7831679 - Prothrombin fragment f 1 + 2 and oral anticoagulant therapy. 15389909 - Home prothrombin time monitoring: a literature analysis. 11717609 - Eustachian valve endocarditis: is it worth searching for? 16972149 - Myocardial perfusion abnormalities in chemical warfare patients intoxicated with mustar... 10540539 - Carotid doppler ultrasonography in young stroke patients. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Thrombosis and haemostasis Volume: 91 ISSN: 0340-6245 ISO Abbreviation: Thromb. Haemost. Publication Date: 2004 Feb |
Date Detail:
|
Created Date: 2004-02-12 Completed Date: 2004-10-19 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 7608063 Medline TA: Thromb Haemost Country: Germany |
Other Details:
|
Languages: eng Pagination: 388-93 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, University Jean Monnet of Saint-Etienne, Saint-Etienne, France. dakosta@aol.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Blood Coagulation Disorders / complications*, drug therapy Case-Control Studies Coronary Angiography Family Health Female Follow-Up Studies Humans Male Middle Aged Myocardial Infarction / complications*, drug therapy Platelet Aggregation Inhibitors / therapeutic use Prognosis Recurrence Risk Factors Thrombosis / etiology Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary...
Next Document: Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major ...